Professional Media briefs: January 2013

Professional Media briefs: January 2013
Professional Media briefs: January 2013

After five years, the Wall Street Journal announced it is ending the Health Blog. A eulogy for the blog by Brian Reid, director at WCG, noted that the WSJ's effort outlasted the “Prescriptions” blog at the New York Times by four months.

In addition to getting its own Facebook page September 10, Nature's Antibodypedia released its seventh version November 29. The free, open-access resource includes a catalogue of more than 500,000 antibodies and the results of around 145,000 experiments. New features include search-refining filters and Nature's manuscript annotation tool. The Facebook page includes Nature-posted queries such as, “How much research do you do when choosing antibodies to purchase? Any suggestions for providers to add?” and newsy posts.

Elsevier has added four medical board review apps. The latest titles are Braunwald's Heart Disease Review and Assessment, Emergency Medicine Review: Preparing for the Boards, Rush University Medical Center Review of Surgery and Sleep Medicine Review: A Problem-Oriented Approach. The titles include a teaser version to give users a sense of the content and can then be purchased from within the app.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.